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Abstract
Background Mannose-binding lectin (MBL) is an innate
immune protein. The aim of our study was to determine whether
genetically determined MBL deficiency is associated with
susceptibility to juvenile rheumatoid arthritis (JRA) and whether
MBL2 genotypes are associated with JRA severity.
Methods In a retrospective cohort study of 218 patients with
polyarthritis (n = 67) and oligoarthritis (n = 151), clinical and
laboratory disease variables were obtained by clinical
examination and chart reviews. Healthy Caucasian adults (n =
194) served as control individuals. MBL2 gene mutations were
determined by Taqman analysis to identify genotypes with high,
medium and low expression of MBL. Functional MBL plasma
concentrations were measured using enzyme-linked
immunosorbent assay. Associations between clinical and
laboratory variables and MBL2 genotypes were determined by
Kruskal-Wallis and χ2 tests.
Results  MBL2  genotype frequencies were similar in
polyarthritis and oligoarthritis patients as compared with control
individuals. MBL plasma concentrations were associated with
the high, medium and low MBL genotype expression groups (P
< 0.01). In polyarthritis patients, the presence of low-expressing
(deficient) MBL2 genotypes was associated with early age at
onset of disease (P = 0.03). In oligoarthritis patients, patients
with low-expressing MBL2  genotypes were more often in
remission (81%) than patients in the medium (54%) and high
(56%) genotype groups (P = 0.02). The remaining clinical and
laboratory variables, such as arthritis severity index, presence of
radiographic erosions and antinuclear antibody positivity, were
not associated with MBL2 genotypes.
Conclusion Genetically determined MBL deficiency does not
increase susceptibility to JRA, but MBL deficiency is associated
with a younger age at onset of juvenile polyarthritis. On the other
hand, MBL-deficient children with juvenile oligoarthritis are more
often in remission. Therefore, MBL appears to play a dual role in
JRA.
Introduction
Juvenile rheumatoid arthritis (JRA), also known as juvenile idi-
opathic arthritis (JIA), is a rheumatic disease of childhood, and
includes a heterogeneous group of patients with differing
characteristics, clinical manifestations, serological parameters
and genetic background. Although the aetiology of JRA
remains unknown, it appears to be a combined action of envi-
ronmental, hormonal and genetic factors [1-3]. It is generally
believed that infections play an important role in the pathogen-
esis of JRA [4].
ANA = antinuclear antibody; CHAQ = Childhood Health Assessment Questionnaire; CRP = C-reactive protein; IQR = interquartile range; MBL = 
mannose-binding lectin; JIA = juvenile idiopathic arthritis; JRA = juvenile rheumatoid arthritis; PGA = physician's global assessment; RA = rheumatoid 
arthritis; RF = rheumatoid factor; SNP = single nucleotide polymorphism.Arthritis Research & Therapy    Vol 10 No 2    Dolman et al.
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Mannose-binding lectin (MBL) is a serum protein, produced in
the liver, that plays an important role in innate immunity and
functions as an opsonin, recognizing sugar structures on a
wide variety of micro-organisms [5]. Serum MBL can directly
opsonize micro-organisms and enhance the uptake by phago-
cytic cells via activation of the lectin pathway of the comple-
ment system [6,7]. Genetically determined functional MBL
serum levels vary within the population. Six single nucleotide
polymorphisms (SNPs) in the MBL2 gene on chromosome 10
are known to influence MBL plasma levels. Reduced or defi-
cient MBL plasma levels are seen in individuals with hetero-
zygous or homozygous SNPs in codons 54 (B mutation), 52
(D mutation), or 57 (C mutation) of exon 1 of the MBL2 gene
[5,8,9]. The variant alleles occur with a combined phenotype
frequency of about 25% to 30% in the Caucasian population
[10,11]. The wild-type is called A, whereas the common des-
ignation for the variant alleles is O. In addition, MBL plasma
concentrations fluctuate in the presence or absence of three
SNPs (position -550: H and L alleles; position -221: X and Y
alleles; and position +4: P  and Q  alleles) in the promoter
region of the MBL2 gene [12,13]. However, only the X/Y vari-
ant has a pronounced influence; the X allele is associated with
decreased plasma MBL levels and the Y  variant with high
plasma MBL levels. Subsequently, intermediately decreased
MBL serum levels are seen in individuals with the genotypes
XA/XA and YA/O, whereas very low or undetectable serum
MBL levels are seen in individuals with genotypes XA/O and
O/O. Individuals with YA/YA and YA/XA haplotypes have high
or normal MBL levels. Therefore, patients can be classified into
high (YA/YA and YA/XA), medium (XA/XA and YA/O) and low
(XA/O and O/O) MBL genotype expression groups [10,14].
MBL deficiency has been associated with increased suscepti-
bility to and severity of infections, especially in children
[15,16]. In addition, it has been suggested that MBL modu-
lates inflammation and autoimmune disease; for example, vari-
ant MBL alleles are risk factors for systemic lupus
erythematosus [17,18]. It has also been suggested that MBL
deficiency is associated with joint erosions and early disease
onset of adult rheumatoid arthritis (RA) [19-23], although
other investigators were unable to confirm such an association
[24,25]. Moreover, it is believed that MBL plays an important
role in innate immunity. Although unproven, it has been hypoth-
esized that infection may trigger JRA in genetically susceptible
patients [26]; this viewpoint suggests that MBL deficiency can
predispose to JRA. In a recently reported study [27], there was
no significant difference in genotypic frequencies of MBL2
codon 54 SNPs between 93 patients with JIA and 48 healthy
control individuals. Codon 57 SNPs were not found. The other
MBL2 SNPs were not investigated in this study. In addition, no
association of MBL2 haplotypes was found between the sub-
groups of patients with JIA and control individuals.
The aim of the present study was to determine whether genet-
ically determined MBL deficiency is associated with suscepti-
bility to JRA and whether MBL2 genotypes are associated
with severity of JRA, as assessed based on patient character-
istics and disease variables.
Materials and methods
Patients and samples
Eligible patients participated in a larger cohort study of Cauca-
sian Norwegian children with JRA and visited the Department
of Rheumatology of Rikshospitalet University Hospital (Oslo,
Norway) for the first time between January 1980 and Septem-
ber 1985 [28,29]. JRA was defined as meeting the American
College of Rheumatology criteria for JRA [30]. The 236
patients from whom blood was drawn were stratified accord-
ing to JRA subgroup, because disease variables vary within
these groups. Patients with systemic arthritis (n = 2) and juve-
nile spondylarthropathy (juvenile ankylosing spondylitis [n = 3],
seronegative enthesopathy [n = 4], juvenile psoriatic arthritis
[n = 11], or inflammatory bowel disease associated arthritis [n
= 1]) were excluded because these subgroups consisted of
too few individuals to permit reliable statistic analysis. Of the
218 remaining patients, 151 had oligoarthritis and 67 had pol-
yarthritis. The patients were examined and interviewed after a
median disease duration of 14.8 years (interquartile range
[IQR] 13.5 to 16.2 years) and their medical records were
reviewed for variables associated with the onset and course of
disease.
Plasma samples were immediately frozen at -80°C. Genomic
DNA was isolated from heparinized/EDTA blood according to
standard procedures. The study is compliant with the Helsinki
Declaration. It was approved by the Regional Ethics Commit-
tee for Medical Research and written informed consent was
given by the parents. Routine laboratory investigations
included C-reactive protein (CRP) level and erythrocyte sedi-
mentation rate, and detection of IgM-rheumatoid factor (RF)
and antinuclear antibodies (ANAs). In addition, MBL plasma
concentrations and genotypes were determined in 194
healthy adult volunteers, who served as control individuals
[10].
Clinical data
Demographic and clinical outcome variables were recorded
from the charts at the follow-up visit. Onset of disease was
defined as the date that arthritis was documented by a physi-
cian for the first time. The clinical examination included a phy-
sician's global assessment (PGA) of overall disease activity
(ranging from 0 to 5) as well as assessment of numbers of
actively involved (swollen or tender and mobility-restricted)
and affected (swollen or mobility-restricted) joints, disease
remission status (current remission, active disease after previ-
ous remission, or continuously active disease) and presence
of uveitis. Furthermore, the number of cumulative affected
joints and the arthritis severity index score were recorded. The
Childhood Health Assessment Questionnaire (CHAQ) was
used to measure physical disability at follow up [31]. ItAvailable online http://arthritis-research.com/content/10/2/R32
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measures physical functioning in the following areas: dressing
and grooming, arising, eating, walking, hygiene, reaching, grip-
ping and activities. The mean CHAQ score ranges from 0 to 3,
where 0 represents no disability and values above 1.5 repre-
sent severe disability.
Radiographic examinations
Radiographs of the sacroiliac joints, hips, ankles and tarsi
were obtained at follow up of all patients, and examined by two
radiologists, who were blinded to patient information and had
no access to earlier radiographic, clinical, or laboratory data.
Radiographs of other affected joints were obtained when clin-
ically indicated. The radiographic changes were classified as
joint erosions (grades III to V) or no joint erosions (grades 0 to
II).
MBL assays
MBL measurements were performed at Sanquin Research
and the Landsteiner Laboratory (Academic Medical Center,
Amsterdam, The Netherlands). MBL plasma levels were meas-
ured using an enzyme-linked immunosorbent assay, as previ-
ously described [14,32]. Briefly, mannose was coated to the
solid phase, and after incubation with plasma, biotinylated
mouse-anti-human MBL IgG (10 μg/ml; Tacx and coworkers
[32], Amsterdam) was used as detection antibody [32].
Genotyping of the promoter polymorphisms and exon 1 SNPs
was performed by allelic discrimination using a Taqman assay,
using specific primers and minor groove binding probes for
each SNP [14,33]. Genotyping was performed independently
of the clinical data collection and MBL plasma level measure-
ments. Patients were classified into three MBL2  genotype
groups with high, medium and low expression of MBL. The
influence of the X/Y allele was also determined by studying six
'extended' genotype groups: YA/YA, YA/XA, XA/XA, YA/O,
XA/O and O/O.
Statistical analysis
Data are presented as median and IQR because clinical and
laboratory variables were not normally distributed. Conse-
quently, the nonparametric Kruskal-Wallis and Mann-Whitney
U tests were used for comparison of these variables. Frequen-
cies between groups were compared by the χ2 or Fisher's
exact test, where appropriate. Multivariate binominal logistic
regression was used to study the association between MBL2
genotype and remission status (active/remission) after adjust-
ment for disease duration. The odds ratio and 95% confidence
interval were calculated. P < 0.05 was considered statistically
significant. Patients were stratified according to remission sta-
tus (active/remission) to explore further the association
between CRP levels and MBL2  genotype in oligoarthritis
patients. For statistical analysis SPSS 12.0.1 software was
used (SPSS Inc., Chicago, IL, USA).
Results
Demographics
The patient group consisted of 59 boys (27%) and 159 girls
(73%), with a median age at diagnosis of 8.0 years (range 0.8
to 15.4 years; Table 1). The median (IQR) follow-up time was
14.8 (13.6 to 16.2) years. Table 1 shows that most patient
characteristics differ between polyarthritis and oligoarthritis
patients (P < 0.05). Therefore, the association between MBL2
genotype and disease was analyzed in the two JRA subsets
separately (see below).
MBL genotype and functional MBL levels in relationship 
to disease
The median (range) MBL plasma concentration was 1.23
(0.01 to 7.59) μg/ml in the 218 JRA patients. Frequencies of
the B, C and D exon 1 mutations in these JRA patients did not
differ significantly from those in control individuals (P = 0.89,
P = 1.00 and P = 0.37, respectively; Table 2). No deviation
from Hardy-Weinberg equilibrium was observed in JRA
patients or healthy control individuals (data not shown). Of the
218 JRA patients, 113 (52%) were in the high genotype
expression group, 71 (33%) were in the medium genotype
group and 34 (16%) were in the low genotype expression
group (Table 2). The frequency of MBL deficiency was similar
in JRA patients and control individuals (odds ratio 1.1, 95%
confidence interval 0.9 to 1.4; P = 0.37). The distribution of
the extended MBL2 haplotypes in the 218 JRA patients was
as follows: 62 (28%) YA/YA haplotype, 51 (23%) YA/XA hap-
lotype, 15 (7%) XA/XA haplotype, 56 (26%) YA/O haplotype,
25 (12%) XA/O haplotype and 9 (4%) O/O haplotype. These
frequencies did not differ significantly from those in control
individuals (P = 0.89) or between the two JRA subgroups (P
= 0.69). MBL plasma concentrations were highest in the YA/
YA  genotype group and almost absent in XA/O  and  O/O
groups (Figure 1). In JRA patients with high, medium and low
expressing haplotypes, the median (IQR) MBL plasma level
was 1.86 (1.23 to 3.26) μg/ml, 0.77 (0.38 to 1.41) μg/ml and
0.07 (0.04 to 0.15) μg/ml, respectively (P < 0.01; Table 2).
The MBL plasma concentrations of the six extended genotype
groups did not differ between polyarthritis and oligoarthritis
patients (P > 0.46).
MBL association with disease parameters
Polyarthritis group
In the 67 patients with polyarthritis, patients in the low MBL2
genotype group were younger (4.4 years, IQR 3.6 to 7.0
years) at onset of disease than the patients in the medium
(10.1 years, IQR 8.4 to 13.0 years) and high (9.5, IQR 5.6 to
13.0 years) genotype groups (P = 0.05; Table 3). This associ-
ation was even stronger after exclusion of the 11 IgM-RF pos-
itive patients (P  = 0.02; data not shown). The same
association was found in the ANA-negative (P < 0.01) but not
in the ANA-positive patients (P = 0.47; data not shown). In the
high genotype expression group, four patients (11%) were
IgM-RF positive, as compared with seven patients (30%) inArthritis Research & Therapy    Vol 10 No 2    Dolman et al.
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the medium genotype group and none in the low genotype
group (P = 0.06). We did not find any association of MBL
genotype groups with other clinical features, such as number
of cumulative affected joints, arthritis severity index, PGA,
CHAQ scores, or number of patients with uveitis, remission, or
severe radiographic erosions, or with laboratory tests such as
ANAs, erythrocyte sedimentation rate, and IgM-RF (Table 3).
CRP levels were similar in the high, medium and low MBL2
genotype group (Table 3), even after stratification for remis-
sion status (P > 0.10; Figure 2). No differences in clinical or
laboratory variables were found between patients with the A/
A, the A/O and the O/O MBL2 genotypes either (data not
shown).
Oligoarthritis group
In the 151 oligoarthritis patients, age at onset was similar in
the high, medium and low genotype expression groups (P =
0.66; Table 4). Patients with oligoarthritis carrying the low
MBL expression genotype were more often in remission (81%)
than patients in the medium (54%) and high (56%) genotype
groups (P = 0.02; Table 4). Multivariate analysis revealed that,
after adjustment for disease duration, patients in the low gen-
otype groups had an odds ratio of 2.5 (95% confidence inter-
val 1.1 to 5.7) of being in remission at follow up, as compared
with patients in the high genotype group (P = 0.04; data not
shown). The median CRP level was 5 mg/l at follow up in the
three genotype groups, but the CRP value distribution differed
statistically significantly (P < 0.01; Table 4) between these
three groups. Figure 2 shows CRP levels and MBL2 geno-
types in patients with a current remission and patients with
active disease with or without a previous remission. When the
patients were stratified according to remission status (remis-
sion versus active), median CRP levels remained statistically
significantly different in patients with active disease as com-
Table 1
Demographic, clinical, and laboratory characteristics of JRA patients, according to disease onset subtype
Characteristic All JRA patients (n = 218) JRA subgroups P
Polyarthritis (n = 67) Oligoarthritis (n = 151)
Demographic variables
Males (n [%]) 59 (27%) 19 (28%) 40 (27%) 0.87
Age (years) at onset 8.0 (3.7 to 11.6) 9.4 (5.5 to 12.9) 7.3 (3.1 to 11.5) <0.01
Disease duration (years) at follow up 14.8 (13.6 to 16.2) 14.6 (13.4 to 16.3) 15.0 (13.8 to 16.2) 0.68
Clinical variables
Number of cumulative affected joints 5 (2 to 15) 20 (11 to 34) 4 (2 to 6) <0.01
Arthritis severity index 2 (0 to 11) 12 (2 to 37) 2 (0 to 5) <0.01
Physician global assessment 1 (1 to 2) 2 (1 to 3) 1 (1 to 2) <0.01
Childhood Health Assessment Questionnaire score 0 (0 to 0.4) 0.1 (0 to 0.6) 0 (0 to 0.3) <0.01
Patients with uveitis (n [%]) 42 (19%) 10 (15%) 34 (23%) 0.27
Remission status at follow-up (n [%])
Current remission 122 (56%) 32 (48%) 90 (60%) <0.01
Active but previous remission 55 (25%) 14 (21%) 41 (27%)
Continuously active 41 (19%) 21 (31%) 20 (13%)
Radiographic erosions grade III to IV (n [%]) 51 (23%) 30 (45%) 21 (14%) <0.01
Laboratory variables
Erythrocyte sedimentation rate (mm/hour) 6 (4 to 13) 7 (4 to 22) 6 (4 to 11) 0.19
C-reactive protein (mg/l) 5 (3 to 6) 5 (3 to 14) 5 (1 to 5) <0.01
Antinuclear antibody positivity 79 (36%) 17 (26%) 62 (41%) 0.03
IgM-rheumatoid factor positivity 11 (5%) 11 (16%) 0 (0%) <0.01
Continuous variables are presented as median (interquartile range [IQR]). JRA, juvenile rheumatoid arthritis.Available online http://arthritis-research.com/content/10/2/R32
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pared with those with a current remission. In these patients,
the median (IQR) CRP level was 4 (1 to 5) mg/l in the high
genotype group versus 5 (4 to 10) mg/l in the medium and 5
(5 to 9) mg/l in the low genotype groups (P < 0.01).
The remaining clinical and laboratory variables did not differ
between the patients in the high, medium and low MBL2 gen-
otype groups (Table 4). The differences found in CRP level
and remission status were also present in patients with the A/
A, the A/O and the O/O MBL2 genotype. Other clinical and
laboratory variables did not differ between these patients (data
not shown).
Discussion
In this study we demonstrated that the frequency of MBL defi-
ciency was not increased in 218 Norwegian Caucasian chil-
dren with JRA as compared with 194 Dutch Caucasian control
individuals. Our observations are in agreement with the only
previous study of MBL conducted in JIA patients [27]. In that
study no association between MBL2 codon 54 mutations and
JIA was found. We have now shown that JRA is also not asso-
ciated with any of the other five known MBL2 SNPs.
The frequency of these mutations also did not differ from the
frequencies identified in previously published Danish Cauca-
sian control populations [10,11]. Over the past few years stud-
ies have been published that consistently reported similar
frequencies in Caucasian populations of different countries
[10,11,34]. Therefore, we assume that the frequencies of
MBL2 gene polymorphism in the Caucasian Norwegian pop-
ulation do not differ from those in other Caucasian popula-
tions. Therefore, our present observations suggest that
genetically determined MBL deficiency is not associated with
increased susceptibility to JRA. Based on the number of
included patients and control individuals, this study has 80%
power when an odds ratio of 1.71 or greater for MBL defi-
ciency is found.
Interestingly, children in the low MBL2 genotype group devel-
oped polyarthritis at a younger age than did children in the
medium or high genotype groups. Previously, Garred and
coworkers [23] showed that MBL2 exon 1 variant allele carrier
status was associated with early age at onset of RA, which is
the adult counterpart of polyarthritis [26]. Garred and cowork-
ers hypothesized that MBL may delay the onset of RA but that
it does not prevent the disease. The mechanism by which MBL
deficiency might promote inflammation in immune-mediated
inflammatory diseases such as RA and JRA is as yet unknown.
MBL deficiency might lead to a diminished innate immunity,
and subsequent increased risk for infections, as was previ-
ously remonstrated [15,16]. These infections may trigger JRA,
as has been hypothesized previously [26]. Another possibility
is that MBL is involved in the recognition of an infectious agent
in the pathophysiology of JRA. Low or absent MBL plasma
concentration leads to decreased complement activation and
ineffective clearance of the pathogen or pathogen-derived
antigens. The prolonged presence of infectious agents in the
host may enhance synovial inflammation because of the proin-
flammatory effects of bacterial DNA and bacterial cell wall
fragments [35,36]. Anti-MBL autoantibodies may also play a
role, because elevated levels of anti-MBL autoantibodies were
found in the sera of RA patients [37]. It is unclear at present
whether MBL deficiency is indeed involved in the pathogene-
sis of RA or JRA, because the data reported are variable.
Furthermore, MBL deficiency does not appear to play a role
once polyarthritis has developed, because no associations
were found between MBL2 genotype and the laboratory vari-
ables or the remaining disease severity related clinical varia-
bles, such as PGA, CHAQ score, number of actively involved
or affected joints, and number of patients with uveitis or remis-
sion. Consistent with the previous report by Barton and cow-
orkers [25] on RA and MBL polymorphisms, we did not find an
association between erosive joint destruction and MBL poly-
morphisms in patients with JRA.
In the oligoarthritis group, patients in the low genotype group
were in remission more often (81%) than were the children in
the medium or high genotype group (54% to 56%). In this
regard, lack of the protein MBL in serum appears to be asso-
ciated with a milder disease course or decreased inflamma-
tion. The possible explanation for these findings might be that
MBL has an immunomodulating effect. MBL is present in syn-
ovial fluid and can bind potential causative agents in JRA
Figure 1
MBL level according to (extended) MBL2 haplotypes in patients with  juvenile polyarthritis and oligoarthritis MBL level according to (extended) MBL2 haplotypes in patients with 
juvenile polyarthritis and oligoarthritis. Median mannose-binding lectin 
(MBL) plasma levels, represented by horizontal lines, differ between 
extended haplotype groups (P < 0.01), but not between patients with 
oligoarthritis (n = 151) and polyarthritis (n = 67) who had similar haplo-
types (P > 0.46).Arthritis Research & Therapy    Vol 10 No 2    Dolman et al.
Page 6 of 11
(page number not for citation purposes)
Table 2
MBL concentrations and MBL2 genotypes
Control individuals All JRA patients JRA subgroups
Polyarthritis Oligoarthritis
Exon 1 mutations
Sum A/A 120 (62) 128 (59) 43(64) 85 (56)
Sum A/O 65 (33) 81 (37) 22 (33) 59 (39)
A/B 40 (21) 43 (20) 14 (21) 29 (19)
A/C 5 (3) 7 (3) 0 (0) 7 (5)
A/D 20 (10) 31 (14) 8 (12) 23 (15)
Sum O/O 9 (5) 9 (4) 2 (2) 7 (5)
B/B 4 (2) 4 (2) 1 (1) 3 (2)
B/C 1 (0) 0 (0) 0 (0) 0 (0)
B/D 2 (1) 3 (1) 1 (1) 2 (1)
C/D 0 (0) 1 (0) 0 (0) 1 (1)
D/D 2 (1) 1 (0) 0 (0) 1 (1)
Total 194 (100) 218 (100) 67 (100) 151 (100)
Genotype groups
High 110 (57) 113 (52) 36 (54) 77 (51)
YA/YA 60 (31) 62 (28) 21 (31) 41 (27)
YA/XA 50 (26) 51 (23) 15 (22) 36 (24)
Medium 52 (27) 71 (33) 23 (34) 48 (32)
XA/XA 10 (5) 15 (7) 7 (10) 8 (5)
YA/O 42 (22) 56 (26) 16 (24) 40 (27)
Low 32 (16) 34 (16) 8 (12) 26 (17)
XA/O 23 (12) 25 (12) 6 (9) 19 (13)
O/O 9 (4) 9 (4) 2 (3) 7 (5)
Total 194 (100) 218 (100) 67 (100) 151 (100)
MBL concentration
High 1.65 (1.20 to 2.69) 1.86 (1.23 to 3.26) 1.87 (1.14 to 3.15) 1.85 (1.32 to 3.67)
Medium 0.52 (0.40 to 0.92) 0.77 (0.38 to 1.41) 0.89 (0.32 to 1.79) 0.73 (0.38 to 1.43)
Low 0.04 (0.02 to 0.13) 0.07 (0.04 to 0.15) 0.10 (0.05 to 0.15) 0.07 (0.04 to 0.17)
Norwegian Caucasian children with juvenile polyarthritis (n = 67) and oligoarthritis (n = 151) are compared with 194 healthy Dutch Caucasian 
adult control individuals. Values are expressed as number (%) or, for continuous variables, as median (interquartile range). Median mannose-
binding lectin (MBL) concentrations and frequencies of exon 1 mutations and MBL2 genotype groups did not differ between all juvenile 
rheumatoid arthritis (JRA) patients and healthy control individuals or within the polyarthritis and oligoarthritis groups (P values > 0.05). A is the 
designation for wild-type; O is the common designation for the variant alleles B (codon 54), C (codon 57) and D (codon 52).Available online http://arthritis-research.com/content/10/2/R32
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including micro-organisms, cellular debris, and agalactosyl
IgG (IgG-G0) [38,39]. Binding of MBL to agalactosyl IgG
immune complexes may result in local complement activation
and subsequent increased inflammation and thus active dis-
ease, whereas this is absent in the presence of very low levels
of MBL [40]. Recently, Troelsen and colleagues [41] found
that high serum levels of MBL and agalactosyl IgG were risk
factors for ischaemic heart disease in RA patients. Besides,
RA patients had higher MBL levels than did their relatives, sug-
gesting that high MBL may trigger RA [39]. Harmful effects of
high MBL levels have been shown in other disease entities as
well. For instance, MBL deposits in the glomeruli can cause
histological damage of kidneys, and activation of the lectin
pathway by MBL can induce vascular tissue damage in myo-
cardial ischemia-reperfusion injury and diabetes [42-44]. On
the other hand, MBL deficiency might be associated with
defective clearance of immune complexes and apoptotic cells,
as seen in individuals with C1q deficiency. Because MBL and
C1q are molecules with similar characteristics this might
explain why during active disease CRP levels were increased
in children in the low compared with the medium and high gen-
otype groups. Remission rates were not associated with
MBL2  genotype in patients with polyarthritis, possibly
because more joints were affected.
Conclusion
MBL appears to play a dual role in JRA. Genetically deter-
mined MBL deficiency does not increase susceptibility to JRA,
but MBL does appear to have an immunomodulating effect.
On the one hand children with low levels of MBL develop pol-
yarthritis at younger age. In the case of MBL deficiency, poten-
tial explanations for this younger age at onset are increased
susceptibility to infections, as a potential trigger of polyarthri-
tis, or ineffective clearance of infectious agents in the patho-
physiology of JRA. On the other hand, the low MBL2
expressing genotypes appear to be beneficial once oligoarthri-
tis has developed, because they are associated with increased
frequency of remission. An explanation may be that the local
MBL itself may lead to complement-mediated inflammation in
the synovium, sustaining active disease. If we are to discover
the possible contribution of MBL to JRA disease severity, then
we must study molecular mechanisms such as the interaction
of MBL with immune complexes, the presence of anti-MBL
autoantibodies and the role of activation of the complement
system.
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Figure 2
CRP and MBL2 genotype: remission versus active disease CRP and MBL2 genotype: remission versus active disease. Shown are serum C-reactive protein (CRP) concentrations (mg/l) and mannose-binding 
lectin (MBL) genotype in patients with a current remission versus active disease (either active disease with a previous remission or continuously 
active disease). *Only CRP values of oligoarthritis patients with active disease (as compared with patients with a current remission) differed statisti-
cally significantly (P < 0.01).Arthritis Research & Therapy    Vol 10 No 2    Dolman et al.
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Table 3
Association of demographic, clinical, and laboratory characteristics and MBL2 genotype expression groups: juvenile polyarthritis
Characteristic MBL genotype expression 
groups
Pa Pb
High (n = 36) Medium (n = 23) Low (n = 8)
Demographic variables
Males 10 (28%) 4 (17%) 5 (63%) 0.05 0.04
Age (years) at onset 9.5 (5.6 to 13.0) 10.1 (8.4 to 13.0) 4.4 (3.6 to 7.0) 0.03 <0.01
Disease duration (years) at follow up 14.6 (13.5 to 16.3) 14.5 (13.2 to 16.4) 15.8 (13.4 to 16.6) NS NS
Clinical variables NS NS
Cumulative affected joints 18 (10 to 32) 22 (10 to 36) 23 (12 to 39) NS NS
Actively involved joints 1 (0 to 4) 2 (0 to 8) 0 (0 to 2) NS NS
Affected joints 6 (2 to 18) 8 (0 to 20) 8 (1 to 27) NS NS
Arthritis severity index 10 (2 to 31) 17 (0 to 46) 19 (2 to 54) NS NS
Physician global assessment 2 (1 to 3) 2 (1 to 4) 1 (1 to 2) NS NS
Childhood Health Assessment Questionnaire score 0.1 (0.0 to 0.6) 0.3 (0.0 to 1.2) 0 (0.0 to 0.3) NS NS
Patients with uveitis 5 (14%) 4 (17%) 1 (13%) NS NS
Remission status at follow up NS NS
Current remission 18 (50%) 10 (44%) 4 (50%)
Active, but previous remission 8 (22%) 4 (17%) 2 (25%)
Continuously active 10 (28%) 9 (39%) 2 (25%)
Radiographic erosions grade III to IV 16 (44%) 10 (44%) 4 (50%) NS NS
Laboratory variables NS NS
Erythrocyte sedimentation rate (mm/hour) 8 (4 to 20) 8 (5 to 25) 3 (0 to 23) NS NS
C-reactive protein (mg/l) 5 (3 to 9) 7 (3 to 18) 5 (4 to 17) NS NS
Antinuclear antibody positivity 10 (28%) 6 (27%) 1 (13%) NS NS
IgM-rheumatoid factor positivity 4 (11%) 7 (30%) 0 (0%) NS NS
Included in this analysis are 67 patients with juvenile polyarthritis. Values are expressed as number (%) or, for continuous variables, as median 
(interquartile range). aComparison of the high, medium and low genotype expression groups by means of the two-sided Fisher's exact test and 
Kruskal-Wallis test. bComparison of the high and medium genotype group versus the low genotype expression group by means of the two-sided 
Fisher's exact test and Mann-Whitney U-test. NS, not significant.Available online http://arthritis-research.com/content/10/2/R32
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Table 4
Association of demographic, clinical, and laboratory characteristics and MBL2 genotype expression groups: oligoarthritis
Characteristic MBL genotype expression 
groups
Pa Pb
High (n = 77) Medium (n = 48) Low (n = 26)
Demographic variables
Males 22 (29%) 10 (21%) 8 (31%) NS NS
Age (years) at onset 6.6 (3.4 to 10.6) 8.7 (2.6 to 12.1) 6.6 (2.9 to 12.6) NS NS
Disease duration (years) at follow up 14.5 (13.6 to 15.9) 15.1 (13.2 to 16.1) 15.3 (14.1 to 16.4) NS NS
Clinical variables NS NS
Cumulative affected joints 3 (2 to 6) 4 (2 to 6) 2 (2 to 4) NS NS
Actively involved joints 0 (0 to 1) 0 (0 to 1) 0 (0 to 0) NS NS
Affected joints 1 (0 to 3) 1 (0 to 2) 1 (0 to 3) NS NS
Arthritis severity index 2 (0 to 6) 2 (0 to 5) 1.5 (0 to 5) NS NS
Physician global assessment 1 (1 to 2) 1 (1 to 2) 1 (1 to 2) NS NS
Childhood Health Assessment Questionnaire score 0.0 (0.0 to 0.3) 0.0 (0.0 to 0.1) 0.0 (0.0 to 0.4) NS NS
Patients with uveitis 12 (16%) 16 (33%) 6 (23%) NS NS
Remission status at follow up 0.02 0.01
Current remission 43 (56%) 26 (54%) 21 (81%)
Active, but previous remission 27 (35%) 13 (27%) 1 (4%)
Continuously active 7 (9%) 9 (19%) 4 (15%)
Radiographic erosions grade III to IV 11 (14%) 8 (17%) 2 (8%) NS NS
Laboratory variables NS NS
Erythrocyte sedimentation rate (mm/hour) 6 (4 to 11) 8 (5 to 13) 5 (4 to 11) NS NS
C-reactive protein (mg/l) 5 (1 to 5) 5 (3 to 6) 5 (5 to 9) <0.01 0.01
Antinuclear antibody positivity 33 (43%) 18 (38%) 11 (42%) NS NS
IgM-rheumatoid factor positivity 0 0 0 - -
Included in this analysis are 151 patients with juvenile oligoarthritis. Values are expressed as number (%) or, for continuous variables, as median 
(interquartile range). aComparison of the high, medium and low genotype expression groups by means of the two-sided Fisher's exact test and 
Kruskal-Wallis test. bComparison of the high and medium genotype group versus the low genotype expression group by means of the two-sided 
Fisher's exact test and Mann-Whitney U-test. NS, not significant.Arthritis Research & Therapy    Vol 10 No 2    Dolman et al.
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